According to a research report by Transparency Market Research (TMR),
the global myasthenia gravis market is anticipated to be worth
US$2,313.1 mn by the end of 2025 from a valuation of US$975.1 mn in
2016. During the forecast period of 2017 and 2025, the global
myasthenia gravis market is projected to clock a CAGR of 10.1%. The
key treatment segments include cholinesterase inhibitors, monoclonal
antibodies, and chronic Immunomodulators. Among the key regional
segments, North America has emerged as a key market for myasthenia
gravis on account of a considerable prevalence of myasthenia gravis
in the U.S.
Report Overview @
https://www.transparencymarketresearch.com/myasthenia-gravis-market.html
The rising prevalence of myasthenia gravis that can impact life
quality is primarily driving the myasthenia gravis market. Myasthenia
gravis is an autoimmune disorder and neuromuscular disorder that
causes muscle weakness. The condition is characterized by
fatigability and weakness of skeletal muscles, wherein development
follows respite. Muscles which are usually impacted are the ones that
monitor swallowing and breathing, eye movement, eye lids, and
shoulder and facial muscles. The condition affects muscles that a
person can control consciously. The weakness of muscles worsens with
movement and improves with rest.
In myasthenia gravis, the muscle cells have difficulties to contract
and respond to nerve impulses which results in weakness of muscles.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26105
Myasthenia gravis is initiated due to a decline in the number of
postsynaptic acetylcholine receptors at neuromuscular joints. This
results in reduction of size of neuromuscular end-plate to
communicate the nerve signal. In a normal state, acetylcholine is
released presynaptically in response to a stimulus resultant in
depolarization that results in muscle action. On the other hand, in
myasthenia gravis, the number of active postsynaptic receptors may be
inadequate to trigger a potential of muscle action. Further, with
repeated stimulus, the decline in release of acetylcholine correlates
with fatigability.
Nevertheless, myasthenia gravis usually does not impact life
expectancy. Patients of myasthenia gravis manage their symptoms and
lead active lives. The condition is prevalent among people of all
ages and ethnicities. Typically, myasthenia gravis is prevalent among
men of middle age and among women between 20 to 30 years of age.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26105
Research and development for therapeutics for myasthenia gravis is
stoking growth of myasthenia gravis market. Symptomatic and casual
treatments are the key therapeutics for myasthenia gravis. The
symptomatic treatment involves increasing the duration of presence of
acetylcholine, which is responsible for transmitting the nerve
impulse by antagonizing acetylcholinesterase.
Despite a largely consolidated vendor landscape with several large
players and a few regional players, competition in the global
myasthenia gravis market is stiff. In this scenario, key players hold
small market shares. Alexion Pharmaceutical Inc., Avadel
Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International
Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda
Pharmaceutical Company Limited, and Valeant Pharmaceuticals
International Inc. are to name some prominent companies in the global
myasthenia gravis market. These companies are focused on research and
development for novel therapeutics for myasthenia gravis. This is one
of the key strategic moves adopted by companies operating in the
myasthenia gravis market. Further, clinical trials to introduce
affordable therapeutics is also an important growth strategy of these
companies.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26105
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
